Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 5% with electrolytes in dextrose 25% provides amino acids for protein synthesis, dextrose for caloric supply, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous; initial adult dose 1.0 g/kg/day of amino acids, up to 1.5 g/kg/day; dextrose rate 5 mg/kg/min initially, titrate to 7 mg/kg/min; daily dose adjusted based on metabolic requirements, electrolytes as per serum levels.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
Not applicable as a single entity; component amino acids have half-lives ranging from minutes (e.g., alanine) to hours (e.g., branched-chain amino acids); dextrose half-life ~1.5-2 hours in normal glucose metabolism; clinical context: continuous infusion maintains steady state.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Renal: amino acids and dextrose metabolites excreted primarily as urea, CO2, and water; electrolytes excreted renally with fractional excretion varying by individual needs; no significant biliary or fecal elimination.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution